Coyote Bioscience is an innovator dedicated to developing point-of-care testing (POCT) solutions and fully automated, integrated rapid molecular diagnostic systems. We fulfill our social responsibility by protecting public health with leading-edge technologies, including our proprietary parallel molecular reaction solution. Driven by the vision “Molecular Diagnostics for Everyone”, Coyote is creating fast, accurate, simple, and portable molecular diagnostic technology.
The word “coyote” comes from Mexican Spanish.
Coyotes are the guardian gods of the Aztecs. They guard the Aztecs and save the injured.
They have followed humans but have never been domesticated.
a guardian god with the heart of a healer in Aztec legends, saves the injured and safeguard people. Coyotes have migrated with humans but have never been domesticated. They are independent and creative. We named the company COYOTE because we hope to be brave to explore the vast world and safeguard everyone's well-being like the coyotes with our innovative molecular diagnostic technology.
Industry leaders from famous universities including Peking University, Tsinghua University, Beijing Institute of Technology, Harvard University, University of California, and Pennsylvania State University are brought together here. Through cooperation with academics and experts, we boast strong abilities to combine instruments, reagents, system platforms with artificial intelligence and big data. We have intellectual proprietaries and technologies in optical electromechanical thermal integration equipment, molecular diagnostic platforms, biochips and biosensors.
Holding the spirit of technological innovation, Coyote focuses on the instrument platform for point-of-care testing (POCT) molecular diagnosis and fully-automated all-in-one molecular diagnosis, and possesses the international patent technology of "Molecular In-Parallel Reaction". The company shows a powerful sense of mission with actions, and safeguards public health with technologies. "Molecular diagnostics for everyone" is the motive force for Coyote to tap into technological innovation, and also the historical mission for the company to fight for the whole human being's wellness.
Year of Establishment
Patents
Provinces and Cities in China
Countries and Regions
Hospitals in China
Total COVID-19 Tests Completed
Coyote has continuously achieved breakthroughs in rapid PCR tests and has been providing technical solutions for epidemics around the globe. By combating against the 2014 Ebola outbreak in Africa and the 2016 Zika epidemic, and undertaking China's key infectious disease project and being validated by the Chinese National Influenza Center in 2018, Coyote has developed a comprehensive solution for major infectious diseases and obtained practical experience over time. Coyote has been recognized by professional institutions and authorities.
When the world is under the shadow of COVID-19 in 2020, Coyote launched the proprietary FlashDetect™ products for COVID-19 testing with the support of state council special task force, and it is internationally patented. Featuring testing at anytime and anywhere with results available in a short time, The FlashDetect™ products can perform efficient testing in target areas, symbolizing that China has taken the lead in PCR testing worldwide.
2014
Ebola Epidemic
2016
ZIKA Pandemic
2018
National Grant for Infectious Diseases
2020
COVID-19 Pandemic
From its headquarters and R&D center in Beijing, Coyote has been growing steadily and has found a GMP in Jiangsu, a R&D center in the United States, and the Coyote medical testing laboratory over the years, forming a complete chain consisting of R&D, production, sales and testing services.
